Clinical Trial Update: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of intratumoral MVR-T3011 given alone or with pembrolizumab in adults with advanced or metastatic solid t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Sarcoma
• Squamous Cell Carcinoma

Drugs mentioned

• MVR-T3011 (T3011)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: ImmVira Pharma Co. Ltd | Conditions: Solid Tumor, Melanoma | Phase 1, Phase 2 | Status: RECRUITING